niacin has been researched along with Diabetic Angiopathies in 27 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "placebo on the incidence of new onset type 2 diabetes mellitus (T2DM) and cardiovascular event rates in patients with normal and impaired fasting glucose (IFG)." | 2.78 | Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose. ( Canner, PL; Maccubbin, D; Sazonov, V; Sisk, CM, 2013) |
| "HDL from patients with type 2 diabetes mellitus and metabolic syndrome has substantially impaired endothelial-protective effects compared with HDL from healthy subjects." | 2.75 | Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. ( Bahlmann, FH; Bahr, MJ; Besler, C; Doerries, C; Drexler, H; Flemmer, S; Haller, H; Heinemann, M; Heinrich, K; Horváth, T; Landmesser, U; Manes, C; Markowski, A; Meyer, M; Mueller, M; Rohrer, L; Sorrentino, SA; von Eckardstein, A, 2010) |
| " A total of 21% of the patients were unable to tolerate niacin owing to reversible side-effects, and 14% were unable to adhere to the niacin dosing regimen of three times daily." | 2.70 | Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes. ( Charles, MA; Kesala, RL; Lin, M; Pan, J; Van, J, 2002) |
| "After an active run-in period, participants were randomly assigned to receive niacin (crystalline nicotinic acid), 3000 mg/d or maximum tolerated dosage (n = 64 with diabetes; n = 173 without diabetes), or placebo (n = 61 with diabetes; n = 170 without diabetes) for up to 60 weeks (12-week active run-in and 48-week double-blind)." | 2.69 | Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. ( Brinton, EA; Davis, KB; Egan, D; Elam, MB; Garg, R; Hunninghake, DB; Johnson, C; Kostis, JB; Sheps, DS, 2000) |
| "Dyslipidemia is an important risk factor for cardiovascular complications in persons with diabetes." | 2.47 | Treatment approaches for diabetes and dyslipidemia. ( Lyons, TJ; Wu, M, 2011) |
| "The lipid profile of type 2 diabetes mellitus is characterized by increased triglycerides (TGs), decreased high-density lipoprotein cholesterol (HDL-C), increased very low density lipoproteins (VLDLs), and small, dense low-density lipoprotein particles, the combination of which is highly atherogenic." | 2.45 | Managing diabetic dyslipidemia: beyond statin therapy. ( Gadi, R; Neeli, H; Rader, DJ, 2009) |
| "Dyslipidemia is characterized by increased triglyceride-rich lipoproteins; low high-density lipoprotein cholesterol; small, dense low-density lipoprotein particles; increased postprandial lipemia; and abnormal apolipoprotein A1 and B metabolism." | 2.42 | Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. ( Cottrell, DA; Falko, JM; Marshall, BJ, 2003) |
| "T1DM-rats were subjected to transient middle cerebral artery occlusion (MCAo) and treated without or with Niaspan." | 1.37 | Niaspan enhances vascular remodeling after stroke in type 1 diabetic rats. ( Chen, J; Chopp, M; Cui, X; Cui, Y; Liu, X; Lu, M; Roberts, C; Shehadah, A; Yan, T; Ye, X; Zacharek, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (25.93) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (33.33) | 29.6817 |
| 2010's | 11 (40.74) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wierzbicki, AS | 1 |
| Sazonov, V | 1 |
| Maccubbin, D | 1 |
| Sisk, CM | 1 |
| Canner, PL | 1 |
| Manoria, PC | 1 |
| Chopra, HK | 1 |
| Parashar, SK | 1 |
| Dutta, AL | 1 |
| Pinto, B | 1 |
| Mullasari, A | 1 |
| Prajapati, S | 1 |
| Hafiane, A | 1 |
| Kellett, S | 1 |
| Genest, J | 1 |
| Pang, J | 1 |
| Chan, DC | 1 |
| Hamilton, SJ | 2 |
| Tenneti, VS | 1 |
| Watts, GF | 2 |
| Barrett, PH | 1 |
| Collins, PD | 1 |
| Sattar, N | 1 |
| Neeli, H | 1 |
| Gadi, R | 1 |
| Rader, DJ | 1 |
| Bitzur, R | 1 |
| Cohen, H | 1 |
| Kamari, Y | 1 |
| Shaish, A | 1 |
| Harats, D | 1 |
| Sorrentino, SA | 1 |
| Besler, C | 1 |
| Rohrer, L | 1 |
| Meyer, M | 1 |
| Heinrich, K | 1 |
| Bahlmann, FH | 1 |
| Mueller, M | 1 |
| Horváth, T | 1 |
| Doerries, C | 1 |
| Heinemann, M | 1 |
| Flemmer, S | 1 |
| Markowski, A | 1 |
| Manes, C | 1 |
| Bahr, MJ | 1 |
| Haller, H | 1 |
| von Eckardstein, A | 1 |
| Drexler, H | 1 |
| Landmesser, U | 1 |
| Natarajan, P | 1 |
| Ray, KK | 1 |
| Cannon, CP | 1 |
| Chew, GT | 1 |
| Davis, TM | 1 |
| Wu, M | 1 |
| Lyons, TJ | 1 |
| Ye, X | 1 |
| Chopp, M | 1 |
| Cui, X | 1 |
| Zacharek, A | 1 |
| Cui, Y | 1 |
| Yan, T | 1 |
| Shehadah, A | 1 |
| Roberts, C | 1 |
| Liu, X | 1 |
| Lu, M | 1 |
| Chen, J | 1 |
| Cottrell, DA | 1 |
| Marshall, BJ | 1 |
| Falko, JM | 2 |
| ASSMANN, F | 1 |
| MENEGHINI, P | 1 |
| AVANZI, G | 1 |
| MCNICOL, GP | 1 |
| DOUGLAS, AS | 1 |
| FEARNLEY, GR | 1 |
| BODE, G | 1 |
| Reasner, CA | 1 |
| Patel, J | 1 |
| Tahrani, AA | 1 |
| Moser, RJ | 1 |
| Meis, SB | 1 |
| Caulin-Glaser, T | 1 |
| Elam, MB | 1 |
| Hunninghake, DB | 1 |
| Davis, KB | 1 |
| Garg, R | 1 |
| Johnson, C | 1 |
| Egan, D | 1 |
| Kostis, JB | 1 |
| Sheps, DS | 1 |
| Brinton, EA | 1 |
| Pan, J | 1 |
| Lin, M | 1 |
| Kesala, RL | 1 |
| Van, J | 1 |
| Charles, MA | 1 |
| Ajjam, ZS | 1 |
| Barton, S | 1 |
| Corbett, M | 1 |
| Owens, D | 1 |
| Marks, R | 1 |
| Noara, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Post-prandial Effects of Extra Virgin Olive Oil on Endothelial Function in Adults at Risk for Type 2 Diabetes: A Randomized Crossover Controlled Trial[NCT04025281] | 20 participants (Actual) | Interventional | 2019-07-09 | Completed | |||
| The Impact of Consumption of Eggs in the Context of Plant-Based Diets on[NCT04316429] | 35 participants (Actual) | Interventional | 2020-06-09 | Completed | |||
| Randomized Clinical Trial to Study the Effect of Extended Release Niacin on Endothelial Function, Oxidative Stress and Endothelial Progenitor Cells in Patients With the Metabolic Syndrome.[NCT00346970] | Phase 4 | 32 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| [NCT00000539] | Phase 3 | 0 participants | Interventional | 1992-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for niacin and Diabetic Angiopathies
| Article | Year |
|---|---|
The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.
Topics: Atherosclerosis; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Management; | 2013 |
Treatment options for low high-density lipoproteins.
Topics: Atherosclerosis; Biomarkers; Cholesterol Ester Transfer Proteins; Diabetes Mellitus, Type 2; Diabeti | 2014 |
Glycaemic Effects of Non-statin Lipid-Lowering Therapies.
Topics: Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabeti | 2016 |
Managing diabetic dyslipidemia: beyond statin therapy.
Topics: Cholesterol, HDL; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Angi | 2009 |
Triglycerides and HDL cholesterol: stars or second leads in diabetes?
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Complications | 2009 |
Triglycerides and HDL cholesterol: stars or second leads in diabetes?
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Complications | 2009 |
Triglycerides and HDL cholesterol: stars or second leads in diabetes?
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Complications | 2009 |
Triglycerides and HDL cholesterol: stars or second leads in diabetes?
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Complications | 2009 |
High-density lipoprotein and coronary heart disease: current and future therapies.
Topics: Acetyl-CoA C-Acetyltransferase; Animals; Apolipoprotein A-I; Biological Transport; Cholesterol Ester | 2010 |
Treatment approaches for diabetes and dyslipidemia.
Topics: Apolipoprotein B-100; Cholesterol, HDL; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus; | 2011 |
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2003 |
PHYSIOLOGY AND PHARMACOLOGY OF FIBRINOLYSIS.
Topics: Adrenocorticotropic Hormone; Adsorption; Anabolic Agents; Biomedical Research; Coronary Disease; Cor | 1964 |
What is the most effective strategy for managing diabetic dyslipidaemia?
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Diabetic Angiopathies; Drug | 2005 |
Dyslipidaemia in diabetes.
Topics: Azetidines; Bezafibrate; Diabetes Complications; Diabetic Angiopathies; Drug Therapy, Combination; D | 2006 |
Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; | 2005 |
6 trials available for niacin and Diabetic Angiopathies
| Article | Year |
|---|---|
Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose.
Topics: Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Meth | 2013 |
Effect of niacin on triglyceride-rich lipoprotein apolipoprotein B-48 kinetics in statin-treated patients with type 2 diabetes.
Topics: Aged; Apolipoprotein B-48; Cardiovascular Diseases; Cross-Over Studies; Delayed-Action Preparations; | 2016 |
Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy.
Topics: Aged; Animals; Cells, Cultured; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diabetic Ang | 2010 |
Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients.
Topics: Aged; Arterioles; Compliance; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combin | 2010 |
Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.
Topics: Aged; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Double-Blind | 2000 |
Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes.
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Diabetic Angiopathies; Huma | 2002 |
9 other studies available for niacin and Diabetic Angiopathies
| Article | Year |
|---|---|
Sugar, sugar.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucose Intolerance; Humans; Hypolipidemic Agents; | 2013 |
Niaspan enhances vascular remodeling after stroke in type 1 diabetic rats.
Topics: Angiotensin I; Angiotensin II; Animals; Blood Glucose; Blood-Brain Barrier; Cerebral Hemorrhage; Cer | 2011 |
[Therapy of peripheral blood circulation disorders with reference to diabetic gangrene].
Topics: Diabetes Complications; Diabetic Angiopathies; Gangrene; Humans; Niacin; Nicotinic Acids; Peripheral | 1959 |
[INDIRECT FIBRINOLYTIC AND ANTICOAGULANT TREATMENT OF THROMBOSIS].
Topics: Anticoagulants; Arteriosclerosis Obliterans; Arteritis; Coronary Disease; Diabetic Angiopathies; Eth | 1964 |
THROMBOLYTIC THERAPY.
Topics: Androgens; Chlorpropamide; Deoxyribonuclease I; Diabetic Angiopathies; Drug Therapy; Fibrinolysin; N | 1964 |
[NEW POSSIBILITIES IN THE DIAGNOSIS AND MEASURES FOR DRUG CONTROL OF DEGENERATIVE VASCULAR DISEASES].
Topics: Anticholesteremic Agents; Arteriosclerosis; Blood Chemical Analysis; Cardiovascular Diseases; Corona | 1964 |
Treating dyslipidaemia in the setting of diabetes mellitus and cardiovascular disease: another focus.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA R | 2006 |
Quantitative evaluation of the dermal vasculature of diabetics.
Topics: Adult; Aged; Benzocaine; Biometry; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetic Angiopathi | 1985 |
[Erythema (2)].
Topics: Adolescent; Adult; Aged; Child; Dermatomyositis; Diabetic Angiopathies; Erythema; Female; Hartnup Di | 1975 |